This trial is a randomized (1:1) phase III open label study of frontline mini-MTX plus methylprednisolone 2mg/kg/day compared to methylprednisolone 2mg/kg in allogeneic stem cell transplant recipients with grade 2-4 aGVHD.
Patients who are fully informed and sign informed consent by themselves or their guardians;
Patients receiving first allogeneic hematopoietic stem cell transplantation;
Patients with acute graft-versus-host disease of grade II-IV were diagnosed after transplantation;
KPS>60, Estimated survival >3 months;
Patients with severe brain, heart, kidney or liver dysfunction unrelated to graft-versus host disease;
Patients with uncontrollable active infection;
Patients with recurrence of primary malignant hematopathy;
Expected survival is less than 3 months